At a glance
ClinicalIndex Comparison RecordN/ACompleted· 460,558 enrolled
Drug / intervention
Empagliflozindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevalence of Cardiovascular Disease in Swedish Patients With Type 2 Diabetes and in Patients Initiating on Empagliflozin
In Brief
An observational study evaluating Empagliflozin for Type 2 Diabetes Mellitus. Completed, enrolled 460,558 participants across 1 site.
Detailed Summary
This study aims to describe the prevalence of type 2 diabetes mellitus (T2DM) patients with established cardiovascular disease (CVD) according to the (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME (ERO)) study definition in a Swedish population. The aim was also to describe the prevalence of established CVD according to ERO study definition in patients with T2DM who initiates treatment with empagliflozin
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesSweden
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
Enrollment StartApr 2018
Primary CompletionNov 2018
First PostedJun 2021
TodayJul 2026
First PostedJun 16, 2021
Enrollment StartApr 2, 2018
Primary CompletionNov 15, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.0 years ago
Interventions
Empagliflozindrug
Empagliflozin